- £3.94bn
- £4.93bn
- $3.16bn
- 83
- 55
- 56
- 76
REG - Hikma Pharmaceutical - Director Declaration
AnnouncementREG - Hikma Pharmaceutical - Hikma acquires Xellia’s assets
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Block listing Interim Review
AnnouncementREG - Hikma Pharmaceutical - Annual Financial Report and Notice of AGM
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Final Results
AnnouncementREG - Hikma Pharmaceutical - Notice of Results
AnnouncementREG - Hikma Pharmaceutical - Agreement in Principle for US Opioid Settlement
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
Announcement